BioCentury | Apr 12, 2010
Strategy

Altheos Mines its Rho-lodex

...also liked Hsu and Kengatharan's experience with ophthalmic drug development at CoMentis. That company (formerly Athenagen Inc....
BioCentury | Jun 2, 2008
Finance

Ebb & Flow

...company APT in October 2007 and in a $50 million B round for neurology company Athenagen...
BioCentury | Jul 16, 2007
Product Development

Wounds: Not open & shut

...ATLN already markets Tracleer to treat pulmonary arterial hypertension (PAH). CoMentis, formerly known as Athenagen...
BioCentury | Feb 26, 2007
Company News

Athenagen neurology, dermatology, ophthalmic news

...The company changed its name to CoMentis Inc. Athenagen Inc. , South San Francisco, Calif. Business: Neurology...
BioCentury | Feb 5, 2007
Clinical News

Mecamylamine: Phase I data

...and did not cause systemic side effects. The compound was dosed twice-daily for 14 days. Athenagen Inc....
BioCentury | Feb 5, 2007
Clinical News

Mecamylamine: Phase II start

...This quarter, Athenagen will begin a double-blind, placebo-controlled, international Phase II trial in 330 patients. Athenagen Inc....
BioCentury | Jan 29, 2007
Product Development

Back-of-the-eye pipeline

...Sirna/Allergan Sirna-027 siRNA targeting VEGF receptor 1 (Flt-1) mRNA Wet AMD Ph I compl (D) Athenagen...
BioCentury | Jan 29, 2007
Product Development

Optical focus

...to complete enrollment of its 36-patient Phase II trial in MMD (MMD-213) by year end. Athenagen Inc....
...are likely to be less costly to the healthcare system than injected ones," Harkonen said. Athenagen...
BioCentury | Oct 30, 2006
Company News

Athenagen management update

Athenagen Inc. , South San Francisco, Calif. Business: Cardiovascular, Cancer, Ophthalmic Hired: John Anthony as VP of non-clinical development, formerly senior director of Schering-Plough Corp.'s Schering-Plough Research Institute; Carl Grove as VP of development operations, formerly...
BioCentury | Oct 2, 2006
Finance

Ebb & Flow

...promoted Ana Stancic to SVP of finance from VP of finance. Private rounds Investors in Athenagen's...
...data from a Phase II trial of GTS-21 to enhance cognition in patients with schizophrenia. Athenagen...
...data for the oral nicotinic acetylcholine alpha-7 receptor in Alzheimer's disease. The proceeds should take Athenagen...
Items per page:
1 - 10 of 28
BioCentury | Apr 12, 2010
Strategy

Altheos Mines its Rho-lodex

...also liked Hsu and Kengatharan's experience with ophthalmic drug development at CoMentis. That company (formerly Athenagen Inc....
BioCentury | Jun 2, 2008
Finance

Ebb & Flow

...company APT in October 2007 and in a $50 million B round for neurology company Athenagen...
BioCentury | Jul 16, 2007
Product Development

Wounds: Not open & shut

...ATLN already markets Tracleer to treat pulmonary arterial hypertension (PAH). CoMentis, formerly known as Athenagen...
BioCentury | Feb 26, 2007
Company News

Athenagen neurology, dermatology, ophthalmic news

...The company changed its name to CoMentis Inc. Athenagen Inc. , South San Francisco, Calif. Business: Neurology...
BioCentury | Feb 5, 2007
Clinical News

Mecamylamine: Phase I data

...and did not cause systemic side effects. The compound was dosed twice-daily for 14 days. Athenagen Inc....
BioCentury | Feb 5, 2007
Clinical News

Mecamylamine: Phase II start

...This quarter, Athenagen will begin a double-blind, placebo-controlled, international Phase II trial in 330 patients. Athenagen Inc....
BioCentury | Jan 29, 2007
Product Development

Back-of-the-eye pipeline

...Sirna/Allergan Sirna-027 siRNA targeting VEGF receptor 1 (Flt-1) mRNA Wet AMD Ph I compl (D) Athenagen...
BioCentury | Jan 29, 2007
Product Development

Optical focus

...to complete enrollment of its 36-patient Phase II trial in MMD (MMD-213) by year end. Athenagen Inc....
...are likely to be less costly to the healthcare system than injected ones," Harkonen said. Athenagen...
BioCentury | Oct 30, 2006
Company News

Athenagen management update

Athenagen Inc. , South San Francisco, Calif. Business: Cardiovascular, Cancer, Ophthalmic Hired: John Anthony as VP of non-clinical development, formerly senior director of Schering-Plough Corp.'s Schering-Plough Research Institute; Carl Grove as VP of development operations, formerly...
BioCentury | Oct 2, 2006
Finance

Ebb & Flow

...promoted Ana Stancic to SVP of finance from VP of finance. Private rounds Investors in Athenagen's...
...data from a Phase II trial of GTS-21 to enhance cognition in patients with schizophrenia. Athenagen...
...data for the oral nicotinic acetylcholine alpha-7 receptor in Alzheimer's disease. The proceeds should take Athenagen...
Items per page:
1 - 10 of 28